Close Menu

circulating tumor DNA

The company recently announced a deal with personalized ctDNA testing firm Natera and will now follow that with the launch of its own MRD product this year.

The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.

The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work. 

The firm said its revenues for the three months ended Dec. 31, 2020 were $78.3 million compared to $62.9 million in the same quarter of 2019.

The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.

Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes.

The group is validating a next-generating sequencing assay that detects EGFR mutations in ultrashort circulating tumor DNA in matched plasma and saliva samples.

The researchers will compare saliva and plasma samples from 50 patients with non-small cell lung cancer to identify circulating tumor DNA in saliva.

The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.

The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.

Pages

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.